BMO Capital Maintains Outperform on Legend Biotech, Maintains $90 Price Target
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Kostas Biliouris maintains an Outperform rating on Legend Biotech (NASDAQ:LEGN) with a $90 price target.
July 03, 2024 | 12:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BMO Capital analyst Kostas Biliouris maintains an Outperform rating on Legend Biotech (NASDAQ:LEGN) with a $90 price target.
The reaffirmation of an Outperform rating and a $90 price target by BMO Capital is a positive signal for investors, likely boosting short-term confidence and potentially driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100